As more biosimilars enter the market that are primarily managed under the pharmacy benefit, there will be an increased need for pharmacists to better understand these biologic products and also be able to provide effective education to patients.
In a new article with Pharmaceutical Executive, Cardinal Health's biosimilars experts discuss pharmacists' comfort levels discussing biosimilars with patients, and how the pharmaceutical industry can help educate.
To read more about how recent research continues to highlight the role education plays in creating clinical confidence among key stakeholders—especially providers, pharmacists, and patients—that ultimately support broader utilization of biosimilars in the market, click here.
